Zentalis Pharmaceuticals

ZNTLPhase 2

San Diego, United Stateszentalis.com

Zentalis Pharmaceuticals is a clinical-stage oncology company dedicated to improving patient lives through innovative cancer therapies. Its core focus is the development of azenosertib, a highly selective WEE1 inhibitor with broad franchise potential, currently in registration-intent Phase 2 and Phase 3 trials for biomarker-defined ovarian cancer. With operations in San Diego and a leadership team experienced in successful biotech exits, Zentalis is strategically positioned to advance its pipeline in areas of high unmet medical need.

Market Cap

$2.9B

Focus

Small Molecules

ZNTL · Stock Price

USD 45.42+22.22 (+95.78%)

Historical price data

AI Company Overview

Technology Platform

Focus on discovering and developing small molecule inhibitors targeting fundamental cancer biology pathways, with core expertise in WEE1 inhibition and a biomarker-driven strategy centered on Cyclin E1 (CCNE1).

Pipeline Snapshot

14 drugs in pipeline

Drug	Indication	Stage
azenosertib	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 2
Zentalis + Gemzar	Advanced Pancreatic Adenocarcinoma	Phase 2
Azenosertib	Uterine Serous Carcinoma	Phase 2
Azenosertib + Niraparib	Ovarian Cancer	Phase 1/2
Azenosertib + Gemcitabine	Osteosarcoma	Phase 1/2

Funding History

Total raised: $506M

PIPE$200MUndisclosedMar 15, 2021

IPO$165MUndisclosedApr 3, 2020

Series B$85MOrbiMedJun 15, 2018

Series A$56MAtlas VentureJun 15, 2015

Opportunities

The primary growth opportunity is the successful development and approval of azenosertib in Cyclin E1+ PROC, a high-need biomarker-defined population.

Further expansion lies in developing azenosertib as a combination backbone with chemotherapy and targeted agents across multiple tumor types, leveraging its mechanism to address a broad range of cancers with replication stress.

Risk Factors

Key risks include clinical failure of the lead asset azenosertib, regulatory hurdles despite Fast Track designation, intense competition from other WEE1 inhibitors and oncology therapies, and financial dependency on capital markets to fund expensive late-stage trials as a pre-revenue company.

Competitive Landscape

Main competitors are other clinical-stage WEE1 inhibitors, most notably AstraZeneca's adavosertib. Zentalis aims to differentiate azenosertib through a potentially best-in-class profile with superior selectivity and a focused, biomarker-driven development strategy in CCNE1+ ovarian cancer.